Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384261 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
A Phase 2 study of Leukemia, Myeloid, Acute, sponsored by OncoVerity.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06384261: Recruiting Phase 2 study of Leukemia, Myeloid, Acute, sponsored by OncoVerity.
NCT06384261 is a Phase 2 study of Leukemia, Myeloid, Acute that is actively recruiting participants, run by OncoVerity. The registered enrollment target is 120 participants, roughly in line with the 112-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06384261, a Phase 2 study of Leukemia, Myeloid, Acute, is actively recruiting participants, sponsored by OncoVerity.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?
Primary Outcome
In all randomized participants
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Cusatuzumab
Study Locations (20)
New York
- Hofstra/Northwell Health - Lake Success
- Cornell University - New York
- University of Rochester Medical Center - Rochester
California
- City of Hope - Duarte
- University of California Los Angeles - Los Angeles
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
- Norton Healthcare, Inc. - Louisville
Alberta
- Tom Baker Cancer Center-Alberta Health Services - University of Calgary - Calgary
- Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta - Edmonton
Arizona
- Banner MD Anderson - Gilbert
Colorado
- University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus - Aurora
Connecticut
- Yale School of Medicine - New Haven
Florida
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT06384261 shows while recruiting
NCT06384261 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 112-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target.
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT06384261 names 20 study sites across 15 states, led by New York, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06384261 about?
NCT06384261 is a clinical study titled "A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy". The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patien...
What is the current status of trial NCT06384261?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-07-22. Estimated completion is 2027-06.
What conditions does trial NCT06384261 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT06384261?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Cusatuzumab (DRUG).
Who is sponsoring clinical trial NCT06384261?
This trial is sponsored by OncoVerity, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06384261 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06384261's enrollment target sits among peer trials
120 11th of 30 higher than 19 of 30 other Leukemia, Myeloid, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia, Myeloid, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 2
-
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
COMPLETED · Phase 2
-
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
COMPLETED · Phase 2
-
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
COMPLETED · Phase 2
-
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
COMPLETED · Phase 2
-
Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI